Cancer Medicine

Open Access

ORIGINAL RESEARCH

Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma Giovanni Marfia1,a, Stefania Elena Navone1,a, Claudia Fanizzi1, Silvia Tabano2, Chiara Pesenti2, Loubna Abdel Hadi 3, Andrea Franzini1, Manuela Caroli1, Monica Miozzo2, Laura Riboni3, Paolo Rampini1 & Rolando Campanella1 1Laboratory of Experimental Neurosurgery and Cell Therapy, Neurosurgery Unit, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, University of Milan, via F. Sforza, 35, Milan 20122, Italy 2Division of Pathology, Department of Pathophysiology and Transplantation, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, via F. Sforza, 35, Milan 20122, Italy 3Department of Medical Biotechnology and Translational Medicine, LITA-Segrate, University of Milan, via Fratelli Cervi, 93, MI Milan, Segrate 20090, Italy

Keywords Angiogenesis, brain tumor, Glioblastoma, glioma., vascular endothelial growth factor, von Willebrand Factor Correspondence Rolando Campanella, Laboratory of Experimental Neurosurgery and Cell Therapy, Neurosurgery Unit, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milan, Italy. Tel: +39 02 0066 0312; Fax: +39 02 5503 8821; E-mail: [email protected] Funding Information The study was partially supported by a grant from the Italian Ministry of Health, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico (GRANT#5x1000-2011). Received: 25 January 2016; Revised: 24 March 2016; Accepted: 2 April 2016 Cancer Medicine 2016; 5(8):1783–1790 doi: 10.1002/cam4.747 aco-first

Abstract Circulating biomarker for malignant gliomas could improve both differential diagnosis and clinical management of brain tumor patients. Among all gliomas, glioblastoma (GBM) is considered the most hypervascularized tumor with activation of multiple proangiogenic signaling pathways that enhance tumor growth. To investigate whether preoperative antigen plasma level of von Willebrand Factor (VWF:Ag) might be possible marker for GBM onset, progression, and prognosis, we retrospectively examined 57 patients with histological diagnosis for GBM and 23 meningiomas (MNGs), benign intracranial expansive lesions, enrolled as controls. Blood samples were collected from all the patients before tumor resection. Plasma von Willebrand Factor (VWF):Ag levels were determined by using a latex particle-­enhanced immunoturbidimetric assay. The median levels of vWF:Ag were significantly higher in GBMs than in meningiomas (MNGs) (183 vs. 133 IU/dL, P = 0.01). The cumulative 1-­year survival was significantly shorter in patients with VWF:Ag levels >200 IU/dL than in those with levels 200 IU/dL, age at surgery >60 years, preoperative KPS 25 cm3, methylated MGMT promoter, absence of 1p/19q deletion, and wild-­type IDH1/2. The results were expressed as crude and adjusted hazard ratios (cHR and aHR) with 95% CI. Starting with the full model, stepwise backward elimination was used as a variable selection procedure. A nominal α level of 0.10 as a cutoff for removing variables was considered. All P-­ values reported are two-­ sided and a value

Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma.

Circulating biomarker for malignant gliomas could improve both differential diagnosis and clinical management of brain tumor patients. Among all gliom...
162KB Sizes 0 Downloads 9 Views